

Addyi® Prior Authorization Request Form (Page 1 of 2)
 DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NP#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:		Dosage Form:
<input type="checkbox"/> Check if requesting brand			Directions for Use:		
<input type="checkbox"/> Check if request is for continuation of therapy					
Clinical Information (required)					
<i>Prescribers must be certified in the Addyi REMs program. Prescribers must review and complete the patient-provider agreement form with every patient prior to prescribing Addyi.</i>					
Select the diagnosis below:					
<input type="checkbox"/> Hypoactive sexual desire disorder (HSDD) with symptoms (low sexual desire that causes marked distress or interpersonal difficulty) that have persisted for at least 6 months					
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
Clinical information:					
Is the patient pre-menopausal? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Is the patient's HSDD related to any other medical or psychiatric condition, substance abuse or relationship issue? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Does the patient have history of alcohol abuse? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Has the patient abstained from alcohol for the past 6 months AND will abstain from alcohol while on Addyi therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No					
<i>Alcohol screening completed at the time of prescribing MUST be attached</i>					
Does the patient have hepatic impairment (Child-Pugh score of ≥ 6 points)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Is the patient using moderate or strong CYP3A4 inhibitors concomitantly? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Reauthorization:					
If this is a reauthorization request, answer the following:					
Has the patient's sexual desire and number of satisfying sexual events increased from baseline? <input type="checkbox"/> Yes <input type="checkbox"/> No					
<i>Chart notes must be submitted documenting improvement in number of satisfying sexual events and symptoms</i>					
Is the patient pre-menopausal? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Will the patient abstain from alcohol while on Addyi therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No					
<i>Alcohol screening completed at the time of prescribing MUST be attached</i>					
Does the patient have hepatic impairment (Child-Pugh score of ≥ 6 points)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Is the patient using moderate or strong CYP3A4 inhibitors concomitantly? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. *Previous therapies will be verified through pharmacy paid claims or submitted chart notes.*					
Prescriber Signature: _____			Date: _____		



Please note: All information below is required to process this request.
Mon-Fri: 6am to 6pm Eastern / Sat: 6am to 6pm Eastern



Addyi[®] Prior Authorization Request Form (Page 2 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-800-711-4555.
This form may be used for non-urgent requests and faxed to 1-800-527-0531.

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**

Office use only: Addyi_Optima_2018Jan-W